Sat, Jan 31, 2015, 9:52 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Zion Oil & Gas, Inc. Message Board

darla73399 7 posts  |  Last Activity: Dec 2, 2014 4:07 AM Member since: Dec 13, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • darla73399 darla73399 Dec 2, 2014 4:07 AM Flag

    We believe that galectin inhibition plays a role in liver fibrosis, and our upcoming Phase 2 clinical trial will increase our scientific understanding of this galectin effect."
    Czirr will be available for one-on-one meetings on the day of the presentation. His presentation will be available as a live and archived webcast at the following address: http://wsw.com/webcast/ldmicro7/galt.
    About LD Micro
    LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm hosts the LD Micro "Main Event" Micro-Cap Growth Conference for investors in December of each year. This year's conference will feature presentations by over 240 publicly traded companies and is expected to attract more than 1,000 attendees. For additional information, please visit the LD Micro conference website at http://www.ldmicro.com.
    About Galectin Therapeutics (GALT
    Loading...
    Loading...
    )
    Galectin Therapeutics (GALT
    Loading...
    Loading...
    ) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

  • Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference
    BY GlobeNewswire
    — 12:30 PM ET 12/01/2014
    NORCROSS, Ga., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (GALT
    Loading...
    Loading...
    ) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James C. Czirr, executive chairman of the Company's board of directors, will present at the LD Micro "Main Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014 at 11:30 a.m. PST at the Luxe Sunset Bel Air Hotel in Los Angeles, Calif.
    The presentation will include a Company overview and financial briefing, a summary of key accomplishments from 2014 including a review of the Company's Phase 1 clinical trial of GR-MD-02 in fatty liver disease with advanced fibrosis, and a discussion of upcoming milestones in 2015.
    Czirr noted, "This year has been a particularly exciting time for Galectin Therapeutics (GALT
    Loading...
    Loading...
    ), as we complete the Phase 1 clinical trial of our propriety galectin inhibitor in fatty liver disease, a condition affecting between nine and 15 million Americans. Liver transplantation is currently the only therapeutic approach to fatty liver disease or other forms of liver fibrosis as there are no drug therapies on the market. What we have seen in our Phase 1 trial is that GR-MD-02 is safe and well tolerated at multiple doses. We also found a reduction for serum biomarker alpha-2 macroglobulin, a key indicator in liver fibrosis. This data was presented by Stephen A. Harrison, M.D., Chief of Hepatology at Brooke Army Medical Center, at the American Association for the Study of Liver Diseases' The Liver Meeting, which represents the largest and most prestigious liver meeting in the world, attended by thousands of physicians, scientists and researchers from around the globe. We believe that galectin inhibition plays a role in liver fibrosis, and our upcoming Phase 2 clinical trial will incr

  • Reply to

    Post from another site ( investors hub ) today

    by giguy_1999 Nov 20, 2014 6:41 PM
    darla73399 darla73399 Nov 22, 2014 12:19 PM Flag

    Amen.....all things are possible with God.....I would have never found out about stock unless my husband was sick.......with liver disease........we were sent to IU........liver transplant team.........from our dr's in Indy........but we do not live in Indy...........they were watching the science of Galt two years ago....and I was told by the transplant dr......when asking about other options....that in the next 10 or 15 years we will not have liver transplants....... so ......the people on the board that are so negative....are probably betting against the company....and making money....not real investors......perhaps this is the real story......too bad...... Shalom

  • All Negative people on this board should sell and leave if they do not believe in the science.....Maybe...the negative people are the ones betting against the company and making money and do not really care about the cure for liver disease........and take down the stock daily....for personally gain........This is what is posted on Fidelity..... about the company..at this time................................................................................................................................Galectin Therapeutics Inc., a development stage company, is engaged in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trials in Europe as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer. Galectin Therapeutics Inc., through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration.

  • Reply to

    Different strategies in investing- jabberwocky

    by giguy_1999 Nov 12, 2014 10:08 AM
    darla73399 darla73399 Nov 22, 2014 6:15 AM Flag

    if you do not believe in the science then sell and get out...Such negative comments.....for people who own the stock .....are you betting against the company.....all the negative people are betting against the company and making money????is this what they constantly post to bring the stock down....so they can profit........ they do not really care about the cure for liver disease.....

  • Reply to

    Tax Selling Will Drive Cesca To New Lows

    by timsoucy822 Nov 18, 2014 1:45 PM
    darla73399 darla73399 Nov 22, 2014 6:01 AM Flag

    if you do not believe or understand the science and ischemic then why are you not selling and be gone....such negativity on this board... unbelievable......the treatment for this is needed....do you even know what ischemic....is and how it looks on the body....if you did .....you would know how important a treatment for this is needed....... all the negativity on the board.......is planned......and for what reason........not hard to figure out......people make big time money betting against companies......also........maybe all these negative people are betting against this company to bring the price down... and make money.....I can not think of any other reason why people would waste time posting negative comments on stock they own......

  • Reply to

    Here's the problem

    by white_sox_curse Nov 12, 2014 12:21 AM
    darla73399 darla73399 Nov 18, 2014 5:20 AM Flag

    Where do you think Galt Clinical trials were done.......I showed the research to doctors in Indianapolis back in 2012 and they said they were watching this .......so take a guess...if these were done at IU then they have something...... check out where they were done.....
    .. And this is where ......The Gilead program is encouraging," said Dr. Naga Chalasani, director of gastroenterology and hepatology at Indiana University Hospital in Indianapolis, who is participating in clinical trials of promising drugs from Gilead and others.
    Drugmakers are working to address the fatty liver disease known as NASH, or nonalcoholic steatohepatitis. Without treatment, NASH can progress to liver-destroying cirrhosis and potentially cancer. Less

ZN
1.500.0000(0.00%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.